



Received: 27 March 2015
Accepted: 15. April 2015
CYSTIC FIBROSIS
Dorian Tješić-Drinković, Duška Tješić-Drinković
Departement of Pediatrics, School of Medicine University of Zagreb,  
and University Hospital Centre Zagreb, Zagreb, Croatia
Summary
Cystic fibrosis is the most common autosomal recessive genetic disease that limits lifespan 
in white populations. Hundreds of mutations have been discovered, with a huge range of clinical 
expressions. Identification of subjects with cystic fibrosis and carriers of the mutation enables 
genetic counseling and disease prevention. Early diagnosis, nowadays often through neonatal 
screening, allows early multidisciplinary approach with a positive impact on longevity and an 
increasing number of adult patients. As more patients live longer, the epidemiological indicators 
change and the number of complications on different organs increase. 
Standardization of care in cystic fibrosis centers with continuous multidisciplinary and lon-
gitudinal follow-up from pediatric age to adulthood contributes largely to better control of the 
disease and improving the quality of life. 
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Cystic fibrosis (CF) is a hereditary disorder with autosomal recessive inheritan-
ce affecting many organs, primarily the respiratory system, the digestive tract and 
the reproductive system [1]. The first disease description dates seventy years ago, 
when patients died mostly in infancy due to severe malabsorption and diarrhea 
[2]. Life-expectancy of patients born nowadays is 50 years of longer [3,4]. Patients’ 
outcome is determinated by the course of lung disease that is the main cause of a 
shortened life-span. 
The disease incidence is approximately 1 in every 3,200 live births in northern 
and western Europe and USA, 1 in 15,000 African-American births and 1 in 32,000 
Asian-American births [5]. Cystic fibrosis is caused by mutations in a single gene 
colloquially called the CF gene that encodes the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) protein [6]. Abnormal chloride conductance in apical membra-
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nes of epithelial cells lining the airways, pancreatic ducts, sweat ducts, intestines, 
biliary tree, and vas deferens results in impaired ion composition of secretions that 
becomes dehydrated and viscous; therefore the alternative name for the disease – 
mucoviscidosis. The consequence of liquid depletion in secretions is mucus obstruc-
tion leading to fibrotic and cystic deformations and finally tissue destruction [4]. 
It is worth mentioning that CFTR has other regulatory functions besides chloride 
transport. By now around 2000 mutations of the CFTR-gene have been described, 
but the functional importance of many is not known. The mutation F508del is found 
in approximately 70% of CF patients in northwestern Europe and USA. 
Within the last decades the life span of CF patients has been notably prolonged, 
thanks to the development of new therapeutical approaches and interventions with 
impact on the disease course. Some important interventions are: disease detection 
through neonatal screening [7], aggressive nutritional support [8], and new trea-
tments for lung inflammation, infection and mucocilliary clearance [9,10,11]. Further 
progress came with exciting new treatments aiming to treat causes rather than just 
symptoms, i.e. mutation-specific therapies allowing read-through of premature stop 
codons, CFTR potentiators and CFTR correctors [12,13]. Nowadays lung transplan-
tation is a treatment option for end-stage lung disease [14]. Specialized CF centers 
with a multidisciplinary team have a crucial, central role in developing and imple-
menting new therapies based on understanding the underlying pathophysiology of 
the disease [15]. 
Despite of well known diagnostic algorithms for classic and non-classic CF [16], 
CF is not always a straightforward diagnosis. There is a small subset of patients, of-
ten adults, who have atypical clinical manifestations [17,18]. Classic CF presentation 
includes pancreatic insufficiency, malnutrition, chronic lung disease and in postpu-
bertal males obstructive azoospermia. The diagnosis is usually suspected within 
the first years of life and easily confirmed. On the contrary, patients with atypical 
presentations are often pancreatic sufficient and have mild clinical symptoms. The 
diagnosis is delayed to adolescence or adulthood, sometimes with the burden of 
equivocal results of diagnostic tests. 
Special challenge present patients that might have CF, but they do not meet 
classic diagnostic criteria for CF, i.e. those having intermediary or normal concen-
trations of chloride in the sweat, those carrying only one mutation or those with a 
monosymptomatic phenotype. These patients are referred to as having a CFTR-rela-
ted disease. It is important to differentiate them from CF patients, for psychological 
and practical reasons, because they have much better prospects [19,20]. 
The clinical syndrome we recognize as CF has considerable variability, and at 
least some of this variability seems to be associated with specific gene mutations. 
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However, individuals with the same genotype can differ considerably, i.e. regarding 
the severity of lung disease. This can be explained by the influence of other intrinsic 
factors like gene modifiers and extrinsic factors such as life-style, environmental in-
fluences, treatment choices etc. [21]. Therefore one should be extremely careful when 
predicting the disease severity and patient’s prognosis merely on the genotype. 
With the prolonged life expectancy of CF patients, especially those born in this 
millennium, there are societies with a bigger proportion of adult patients than chil-
dren. In Canada the median age of survival has increased from 37.3 years in 2002 
to 47.7 years in 2012. [4]. The proportion of adult patients in Croatia is constantly 
increasing in the past two decades as well; they are 1/5 of all registered patients [22]. 
Patophysiology
Most studies regarding how CFTR dysfunction leads to the phenotypic disease 
were performed on epithelial cells of CF airway samples. Bulk of evidence suggests 
that the main features are diminished chloride efflux to the lumen and excess so-
dium and water reabsorption, leading to dehydration of airway surface materials. 
Airway surface liquid depletion is thought to impair mucociliary clearance. Thus, 
the viscous mucus accumulates obstructing the airways and phlegm harbors pat-
hogenic bacteria. The clinical consequence is persistent cough and bronchitis, often 
accompanied with broncho-obstruction – the earliest clinical signs of impaired lung 
function in CF. 
With time, mucus on the epithelium forms plaques with anaerobic niches that 
can bind opportunistic bacterial pathogens. Characteristically, Pseudomonas aerugi-
nosa over time adjusts to this media, synthesizes an alginate coat and forms biofilms 
that are very difficult to clear with standard antibiotic treatment. The consequence 
of this is a vicious circle of phlegm retention, infection and chronic neutrophil infla-
mmation that perpetuates itself [5,9,23]. 
Many patients develop a pronounced inflammatory reaction already in early 
age, prior to infections. This is believed to be a direct effect of CFTR dysfunction 
leading to dysregulated host inflammatory response. In any case, a strong and con-
stant neutrophilic airway inflammation enhanced with chronic infection and other 
inflammatory stimuli is a milestone of CF airway disease [5,9].
Impaired electrolyte conductance contributes to an impaired bioelectric poten-
tial difference (PD) across the epithelial membrane. The PD can be measured in vivo 
in the nasal epithelium and in vitro in rectal biopsies. Assessing basal PD and chan-
ges in response to various stimuli is used as a diagnostic tool in doubtful cases and 
in research laboratories to test the effectiveness of new drugs for CF [5,9]. 
Rad 522. Medical Sciences, 41(2015) : 65-75
D. Tješić-Drinković, D. Tješić-Drinković: Cystic fibrosis
68
The pathophysilogy of changes within the pancreas are similar to those in the 
airways: dysfunctional CFTR gene leads to lack of chloride secretion in pancreatic 
ducts and as a consequence reduced chloride/bicarbonate exchange, resulting in a 
smaller volume of pancreatic juices that is rich in proteins and poor in bicarbonates. 
These alterations are responsible for obstruction and autodigestion of the pancreas 
that starts early in embryonic life, causing exocrine pancreatic insufficiency at birth 
or within the first months or years of life [24]. 
Impaired ion conductance exists in bile ducts and in vas deferens as well; viscous 
secretions obstruct the canals and lead to reactive inflammation and finally fibrotic 
degeneration [25]. 
In contrast to epithelial cells, the functioning CFTR protein in sweat glands ena-
bles reabsorption of salt and water from the sweat. Therefore the sweat concentra-
tion of chloride and sodium is increased in CF and this is the main laboratory test 
to diagnose the disease. Only a small proportion of patients (1- 2%) with some rare 
mutations have normal sweat electrolyte concentrations [26].
Clinical features 
Lung disease is present in virtually all CF patients and is the determining factor 
of survival. Some patients experience early respiratory symptoms in infancy with 
nonproductive, exhausting cough. Symptoms mimic bronchiolitis with obstructive 
dyspnea and wheezing. However, the lung disease may evolve gradually, in months 
and even years, presenting as chronic broncho-obstruction, bronchitis, recurrent 
pneumonias and hyperinflation of the lung parenchyma. As the disease progresses, 
peribronchal fibrosis, athelectasis and bronchiectasis develop. Attributes of chronic 
lung disease are chronic respiratory insufficiency and cor pulmonale [8,23]. 
In addition to chronic lung disease patients experience pulmonary exacerbati-
ons, sometimes pneumothorax in the advanced disease. In adolescents and adults 
(rarely in children) one should consider allergic bronchopulmonary aspergillosis in re-
fractory exacerbations. 
Initialy, the pathogens causing lung infection are common microorganisms for 
the age of the child (viruses, Haemophylus and Pneumococcus strains). later, usual 
isolates are Pseudomonas aeruginosa, Staphylococcus aureus, and Burkholderia cepacia. 
Pseudomonas infections are difficult to eradicate due to its’ capacity to transform 
and form biofilms [26]. 
Chronic pancreatic insufficiency is present in 85% of the CF population. Lack of 
exocrine pancreatic secretion leads to maldigestion and secondary malabsorption, 
steatorrhoea and increased intestinal nitrogen loss [24]. Malnutrition, specifically 
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long-lasting energy deficiency, has a negative impact on the respiratory system, en-
hancing the number of lung infections and degree of inflammation that favor struc-
tural changes in the airways [24,26]. 
Endocrine function of langerhans islets is usually maintained until adolescence 
and adulthood. Finally about one third of patients develop cystic fibrosis related dia-
betes (CFRD), a unique form of diabetes that has characteristics of type I and type II 
diabetes [27]. 
Neonates with CF can present with transient cholestatc jaundice caused by 
obstruction of intrahepatic bile ducts. Older patients are at risk for focal billiary cirr-
hosis, but clinically apparent liver disease occurs in only a small portion of patients 
and usually presents by 15 years of age. Liver failure is the second leading cause of 
death in CF [26]. 
Neonates can also present with meconium ileus. Older children and adults can 
develop distal obstructive syndrome (DIOS), a syndrome of partial or complete postne-
onatal distal small bowel obstruction caused by stool plugs, also known as meconi-
um ileus equivalent [5,9].
As a consequence of the chronic inflammation, hypomotility, recurrent infections 
and frequent antibiotic use CF patients can develop small bowel bacterial overgrowth 
syndrome, one of the factors contributing to malabsorption and malnutrition [28]. 
Excessive loss of sodium and chloride through sweating sometimes causes hypo-
natriemic dehydration and hypochloremic metabolic alkalosis. This metabolic imbalance 
can be the presenting symptom in early infancy [29]. 
Growth and thriving largely depends on adequate substitution of pancreatic 
enzymes and hypercaloric nutrition. Often, puberty is delayed for one or two years 
due to impaired growth and maturation [29]. 
Most male patients (98%) are azoospermic and unfertile due to vas deferens 
obstruction, with normal other reproductive functions. Women are fertile, althou-
gh they may experience difficulties in getting pregnant due to dehydrated cervical 
secretions [30]. 
Diagnosis
CF is primarily a clinical diagnosis. It should be suspected in any child who 
demonstrates typical clinical features of CF or who was born to a family with a 
known history of CF or has a positive newborn screening. Suspicion is followed by 
laboratory testing to prove CFTR dysfunction. This includes either measuring sweat 
chloride concentration, or genetic testing, or measurement of the nasal PD [31]. The 
sweat test is the long-standing standard and mostly used to confirm CF. Mutation 
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identification is not obligatory for the diagnosis in patients with clinical symptoms 
and elevated sweat chlorides. However, knowing the mutations is relevant for fami-
ly genetic counseling and important because some mutations can be corrected with 
the new therapies.
Neonatal screening has been implemented in many countries. This allows disease 
detection in the pre-symptomatic phase. Early implementation of various therape-
utical procedures should provide better disease control; ensure optimal nutritional 
status and altogether better prognosis [7]. 
Treatment options
CF treatment consists of life-lasting measures to control symptoms and disease 
progression, as there is still no causative therapy [9]. However, alternative drug tre-
atment that affects intercellular function, like trafficking, expression or function of 
CFTR has emerged. One of these mutation specific treatments is registered for use in 
2012.y: a CFTR potentiator ivacafor (Kalydeco) for patients with G551D mutation. In 
progress and with promising results are studies with a corrector compound (VX809, 
lumakaftor) and a drug that induces read-through of premature stop codons in cla-
ss I mutations (PTC124-ataluren). Some more substances targeting different ways of 
correcting the CFTR function or biochemical aberrations of CF are under investiga-
tion [32].
While waiting for therapies that treat the basic defect, the milestone of CF thera-
py remains symptomatic treatment. It is mostly focused on respiratory and gastroin-
testinal symptoms with nutritional support. 
Respiratory treatment is focused on managing infection, inflammation and im-
proving airway clearance, and, for end stage lung disease, lung transplantation (9). 
Infections. Aggressive antibiotic therapy was one of the main contributors to 
longer survival of CF patients. Patients move from phases of rather stable lung di-
sease with occasional exacerbations to the state of chronic infection. In each phase 
antibiotic treatment plays an important role. Antibiotics can be given intravenously, 
orally and in inhalations. Nowadays inhaled antibiotics (tobramycin, colistin, aztre-
onam) are the treatment choice for both early Pseudeomonas eradication and control 
of chronic colonization [26,33,34].
Inflammation. Neutrophil-dominated inflammation in the airways is a hall-
mark of CF. Although the mechanism leading to pronounced inflammation is not 
well understood, inflammation contributes to lung damage and disease severity. 
Oral corticosteroids yield improvement in lung function and reduce pulmonary exa-
cerbations, but their use is highly limited due to unacceptable adverse event profile. 
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Unfortunately, inhaled corticosteroids have no proven effect on the course of CF lung di-
sease and are not recommended unless marked bronchial hyper-reactivity is present. 
High dose oral ibuprofen was shown to be effective in slowing the decline in 
FEV1, but it is not an accepted treatment in all centers [5,35].
Macrolide antibiotics have received attention in CF because of their remarkable 
effect in patients with diffuse panbronchiolitis. Azitrhomycin is nowadays recogni-
zed and advised as an immunomodulatory agent for CF, but the exact mechanism 
of action remains unclear. 
Mucolytic therapy. Airway surface liquid depletion and viscid airway secreti-
ons are also a hallmark of CF. Mucolytics such as N-acetylcysteine have little effect on 
lung disease in these patients. On the contrary, inhaled donorase-alfa (recombinant 
human DNAse) effectively reduces sputum viscosity and number of exacerbations, 
and improves lung function in patients with mild to modest lung disease [36]. 
Short –term hypertonic saline solution improves lung function in CF patients, but 
long-term effects have to be yet proven. Inhaled powdered mannitol (Bronchitol, Ardi-
ol) is an alternative and acceptable mucolytic [36]. 
Lung transplantation. This is the final therapeutic option for end-stage lung di-
sease. In the past decades the procedure itself and post-transplant care have impro-
ved substantially [37]. The best timing and selection of candidates for transplantati-
on are still a matter of dispute. It is important to recognize that lung transplantation 
is not a cure for CF patients, but represents a transfer to a new health-state in wich 
all other manifestations of CF persist and may worsen. 
Airway clearance techniques. Chest physical treatment is an inevitable part of 
CF care. There are many techniques: simple percussion, different methods aiming 
to provoke coughing, high frequency chest wall oscillatory drainage, autogenic dra-
inage etc. The choice depends on technical availability, competence of the staff, age 
and preferences of the patient. 
Active immunization is an important issue. Patients should follow the national 
program. No consensus has been reached about extra immunization so far, but the-
re are sugestions that vaccination against pneumoccocus, chickenpox, the flu and 
hepatitis A are beneficial [38]. 
Gastrointestinal system and nutrition. With longer survival of CF patients the 
numbers of gastrointestinal complications increase. Therefore collaboration with 
other specialists like gastroenterologists, endocrinologists, dietitians etc. is an im-
perative. 
Nutritional therapy is based on three main components: pancreatic enzyme re-
placement, vitamin supplementation and quantitatively and qualitatively balanced 
diet ensuring at least 20% more calories than the RDA values in order to meet raised 
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energy demands caused by the hypermetabolic state [39]. Patients with CF and poor 
nutritional status are more prone to lung infections and earlier decline in FEV1, so 
gastroenterological therapy must be included in everyday care. 
Conclusion
When CF is suspected in the presence of typical clinical features it must be con-
firmed by laboratory testing. The awareness of doctors to recognize the symptoms, 
especially pediatricians who see patients at an early age is crucial for detecting the 
disease, therefore competence should be worked on.
Neonatal screening enables detecting the disease in asymptomatic individuals. 
However, it raises some controversies and new challenges regarding treatment and 
prevention of complications. Main determinants of CF outcome is early detection 
and good control of pulmonary disease, that can be achieved through multidisci-
plinary treatment including a pulmonologists, gastroenterologists, dietitians and 
other specialties. With better care and longer lifespan of many patients we are wit-
nessing a dramatic increase in the proportion of adult patients, in some countries 
surpassing the pediatric population. This brings new challenges, especially for doc-
tors in adult medicine who face some new and less known CF presentations emer-
ging during the life course. 
It is now well established that best care for CF patients is provided in specialized 
CF centers that ensure multidisciplinary and longitudinal follow-ups of patients 
from infancy to adulthood, taking in consideration special needs and difficulties 
in translation from pediatric to adult CF units. Based on European experiences and 
published recommendations for standards of care, it is imperative to reorganize me-
dical care for CF patients in Croatia, where already one fifth patients are adults [22]. 
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Sažetak
Cistična fibroza
Cistična fibroza je najčešća nasljedna, autosomalno recesivna bolest koja utječe na dužinu 
života u bijeloj rasi. Danas je prepoznato više stotina mutacija uz veliku varijaciju ekspresije 
bolesti. Prepoznavanje bolesnika i nosilaca mutacije pruža mogućnost genskog savjetovanja i 
prevencije bolesti. Rano dijagnosticiranje, sve češće pomoću neonatalog probira, omogućuje 
rani multidisciplinarni terapijski pristup uz značajno produljenje životnog vijeka i sve većeg broja 
odraslih bolesnika. Dužinom životnog vijeka mijenjaju se epidemiološki pokazatelji bolesti te se 
uočava sve više komplikacija bolesti na drugim organskim sistemima.
Osnivanje specijaliziranih centara za liječenje cistične fibroze s multidisciplinarnom longitu-
dinalnom skrbi za bolesnike od pedijatrijske do odrasle dobi predstavlja daljnji doprinos kontroli 
bolesti i kvalitete života bolesnika.
Ključne riječi: cistična fibroza; patogeneza; klinička slika; dijagnostika; liječenje.
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